NMT would like to extend our sincere congratulations to astronauts
Chris Hadfield and Tom Marshburn who have successfully docked with the International Space Station (ISS) on December 21st as part of the 5 month Expedition 34 crew.
American Tom Marshburn, Russian Roman Romanenko and Canadian Chris Hadfield travelled two days in the Soyuz capsule before linking up with the space station's Russian Rassvet research module. The docking took place approximately 255 miles (410 kilometers) above the capital of Kazakhstan. They will remain at the orbiting research laboratory for 5 months until May 2013.
Chris Hadfield and Tom Marshburn were also part of the NEEMO 14 mission onboard the Aquarius undersea habitat in 2010. As part of that mission both Chris and Tom wore NMT’s state-of-the-art Radio Frequency Impedance Interrogation (RFII) ETag technology demonstrating the use of wireless biomedical monitoring from the sea floor. This successful demonstration paved the way for use of the RFII technology in austere and extreme environments including spaceflight and microgravity which was successfully completed in 2012. We wish Chris and Tom and the rest of the Expedition 34 crew godspeed, a successful mission and a safe journey home.
In addition, NMT also successfully completed and received their FDA 510(K) clearance for their ZOE device in November 2012. This clearance will now open the door for many new and exciting markets including renal and dialysis patients in 2013. NMT continues to push the limits and capabilities of non-invasive medical monitoring to ensure the highest standards of patient care and to remain at the forefront of innovative biomedical monitoring research and development.
Since our founding in 2003, NMT has made remarkable progress in bringing to market a comprehensive suite of innovative noninvasive hemodynamic monitoring and assessment tools and solutions that provide both military and civilian medical specialists with real-time situational awareness and critical lifesaving intelligence. In this regard, we are fast approaching full commercialization of cutting edge, innovative products that we believe each hold potential to materially change the universal standard of medical care.
NMT manufactures its patented noninvasive hemodynamic monitors for use across the care continuum. Our clinical and administrative staff collectively has many years of development work in the field of bioimpedance application.
NMT is the only cardioplethsmograph company that incorporates the patented three-dimensional signal averaging into our technology. In addition NMT leads the world in research and development of new and innovative uses for noninvasive hemodynamic monitoring.
NMT truly has no direct competitor. Our products target markets spanning across the care continuum, as opposed to other companies that claim to be a global leader in patient monitoring, yet only cater to a single demographic in the world of healthcare. Our core competencies are many as we consistently learn of new and innovative applications for our technology. NMT views it as our duty and corporate culture to push the boundaries of noninvasive patient monitoring by continually exploring new frontiers in support of our mission.
To save lives by continually advancing the standard for noninvasive patient monitoring across the care continuum, while maximizing clinical, medical, and financial outcomes, and promoting scientific innovation.
Again, welcome to NMT. We sincerely appreciate your interest in our company!